Loading...

MRSN MERSANA THERAPEUTICS INC US FDA Inspections 8-K Filing

MRSN

MRSN

MERSANA THERAPEUTICS INC

(MRSN)

2023 8-K

Show Summary

Summary

Loan Defaults (Secured, Uns...

Reverse Stock Split

New Product Launches

Financial Statements

Management Changes

Financial Results

Corporate Update

Corporate Update

Clinical Trial Update

Stock Exchange Agreement

Financial Results

Financial Results

Annual Meeting of Stockholders

Earnings Report

Sales Agreement

Financial Results Announcement

Disclosure and Business Upd...

Termination of Agreement

Financial Results Announcement

FDA Clinical Hold Lifted

Financial Results Announcement

Financial Results and Restr...

Clinical Hold Announcement

Amendment and Annual Meeting

Earnings Reports

Bylaws Amendments

Loan Agreement Amendment

Financial Results Announcement

Presentation and Clinical T...

Disclosure and Other Events

Financial Update

External Links:

Mersana Therapeutics announces that the FDA has lifted the clinical hold on their Phase 1 clinical trial of XMT-2056.

AI Assistant

MERSANA THERAPEUTICS INC

2023

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.